Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Merck KGaA buys Silence in $1.3B deal for blood cancer drug
Germany’s Merck KGaA picked up Silence to the tune of $1.3 billion following the biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
James Waldron
Oct 19, 2026 8:57am
China looks to ban foreign acquisitions of key biotech platforms
Oct 16, 2026 10:38am
ADARx scores upsized $446M IPO, while City maps out Nasdaq plans
Sep 25, 2026 2:46am
AbbVie-backed ADARx plans IPO to fund array of siRNA med trials
Sep 6, 2026 2:25pm
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
AstraZeneca pays CSPC $30M to form kidney drug discovery pact
Jul 3, 2026 8:00am